Heartflow (NASDAQ:HTFL) Reaches New 1-Year High After Analyst Upgrade

Key Points

• Heartflow shares reached a new 52-week high after JPMorgan raised its price target from $35 to $45 and maintained an overweight rating. The stock traded as high as $43, while analysts’ consensus rating remained “Moderate Buy” with an average target of $43.43.
• Second-quarter revenue rose 47.7% year over year to $64.1 million, while the adjusted loss of $0.07 per share beat estimates. Management also raised 2026 revenue guidance to $246 million–$250 million from $228 million–$232 million.
• Insiders have continued selling shares under pre-arranged Rule 10b5-1 plans, including CEO John C.M. Farquhar’s sale of 38,900 shares. Insiders sold 115,805 shares worth about $3.5 million over the last quarter, though they still own 7.7% of the company.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) shares reached a new 52-week high on Saturday after JPMorgan Chase & Co. raised their price target on the stock from $35.00 to $45.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Heartflow traded as high as $43.00 and last traded at $42.08, with a volume of 9908709 shares changing hands. The stock had previously closed at $31.01.

A number of other equities research analysts also recently commented on the stock. Freedom Capital raised shares of Heartflow to a "strong-buy" rating in a research report on Tuesday, June 30th. William Blair began coverage on Heartflow in a research note on Monday, May 4th. They issued an "outperform" rating on the stock. Robert W. Baird set a $45.00 price objective on Heartflow in a report on Friday. Wells Fargo & Company upped their price objective on Heartflow from $37.00 to $39.00 and gave the company an "overweight" rating in a research report on Friday. Finally, Piper Sandler reissued an "overweight" rating and issued a $45.00 target price (up from $38.00) on shares of Heartflow in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $43.43.

Insider Buying and Selling

In other news, CEO John C.M. Farquhar sold 38,900 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total value of $1,361,500.00. Following the completion of the sale, the chief executive officer directly owned 457,935 shares of the company's stock, valued at $16,027,725. This represents a 7.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the firm's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the sale, the insider owned 78,731 shares in the company, valued at $2,231,236.54. The trade was a 10.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 115,805 shares of company stock valued at $3,530,609. Company insiders own 7.70% of the company's stock.

Heartflow News Roundup

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
• Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
• Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
• Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
• Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Institutional Trading of Heartflow

Several institutional investors have recently made changes to their positions in HTFL. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow in the 4th quarter worth approximately $27,000. Russell Investments Group Ltd. purchased a new stake in Heartflow during the 4th quarter valued at approximately $45,000. Essential Partners LLC bought a new stake in shares of Heartflow during the first quarter valued at approximately $57,000. Legal & General Group Plc purchased a new position in shares of Heartflow in the third quarter worth $59,000. Finally, Strs Ohio bought a new position in shares of Heartflow during the fourth quarter worth $99,000.

Heartflow Price Performance

The stock has a market cap of $3.63 billion and a P/E ratio of -22.99. The stock's 50-day moving average is $29.08 and its two-hundred day moving average is $27.80.

Heartflow (NASDAQ:HTFL - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.15. The company had revenue of $64.08 million for the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.50%. The company's quarterly revenue was up 47.7% on a year-over-year basis. On average, analysts anticipate that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Heartflow Company Profile

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source